Iteos Therapeutics Inc Market Cap ($448.68 Million)
Market Cap & Net Worth: Iteos Therapeutics Inc (ITOS)
Iteos Therapeutics Inc market cap. Iteos Therapeutics Inc (NASDAQ:ITOS) has a market capitalization of $448.68 Million ($448.68 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #12533 globally and #3136 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Iteos Therapeutics Inc's stock price $10.15 by its total outstanding shares 44205400 (44.21 Million). Also see ITOS operating cash flow for how efficiently the company converts equity into cash flow.
Iteos Therapeutics Inc Market Cap History (2020–2025)
Iteos Therapeutics Inc market cap history from 2020 to 2025. Data shows change from $1.50 Billion to $448.68 Million (-11.61% CAGR). Check Iteos Therapeutics Inc (ITOS) stock price for real-time trading data and today's change.
Index Memberships
Iteos Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.02% | #341 of 976 |
|
NASDAQ Composite
IXIC
|
$40.12 Trillion | 0.00% | #1254 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.02% | #189 of 263 |
Weight: Iteos Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Iteos Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Iteos Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Iteos Therapeutics Inc growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
9.70x
Iteos Therapeutics Inc's market cap is 9.70 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $2.06 Billion | $344.77 Million | $214.52 Million | 5.97x | 9.59x |
| 2022 | $863.33 Million | $267.63 Million | $96.65 Million | 3.23x | 8.93x |
| 2023 | $484.05 Million | $12.60 Million | -$112.64 Million | 38.43x | N/A |
| 2024 | $339.50 Million | $35.00 Million | -$134.41 Million | 9.70x | N/A |
Competitor Companies of ITOS by Market Capitalization
Companies near Iteos Therapeutics Inc in the global market cap rankings as of November 5, 2026. Also see Iteos Therapeutics Inc assets under control for a full breakdown of the balance sheet.
Key companies related to Iteos Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Iteos Therapeutics Inc (2020–2025)
Market capitalization of Iteos Therapeutics Inc from 2020 to today. Between 2020 and today, Iteos Therapeutics Inc's market cap moved from $1.50 Billion to $ 448.68 Million, with a yearly change of -11.61%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $448.68 Million | +32.16% |
| 2024 | $339.50 Million | -29.86% |
| 2023 | $484.05 Million | -43.93% |
| 2022 | $863.33 Million | -58.05% |
| 2021 | $2.06 Billion | +37.67% |
| 2020 | $1.50 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 28th, 2026 the market cap of Iteos Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $448.68 Million USD |
| MoneyControl | $448.68 Million USD |
| MarketWatch | $448.68 Million USD |
| marketcap.company | $448.68 Million USD |
| Reuters | $448.68 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Iteos Therapeutics Inc
iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lym… Read more